📣 VC round data is live. Check it out!

SOPHiA Genetics Valuation Multiples

Discover SOPHiA Genetics' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Prenetics Global, TaiDoc Technology, ToolGen, Medical Data Vision and more.

SOPHiA Genetics Overview

About SOPHiA Genetics

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.


Founded

2011

HQ

France

Employees

423

Financials (LTM)

Revenue: $84M
EBITDA: ($38M)

EV

$348M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

SOPHiA Genetics Financials

SOPHiA Genetics reported last 12-month revenue of $84M and negative EBITDA of ($38M).

In the same LTM period, SOPHiA Genetics generated $57M in gross profit, ($38M) in EBITDA losses, and had net loss of ($73M).

Revenue (LTM)


SOPHiA Genetics P&L

In the most recent fiscal year, SOPHiA Genetics reported revenue of $77M and EBITDA of ($42M).

SOPHiA Genetics is unprofitable as of last fiscal year, with gross margin of 67%, EBITDA margin of (54%), and net margin of (102%).

See analyst estimates for SOPHiA Genetics
LTMLast FY202320242025202620272028
Revenue$84M$77M$62M$65M$77M
Gross Profit$57M$52M$43M$44M$52M
Gross Margin68%67%69%67%67%
EBITDA($38M)($42M)($70M)($51M)($63M)
EBITDA Margin(45%)(54%)(112%)(78%)(82%)
EBIT Margin(79%)(92%)(120%)(102%)(92%)
Net Profit($73M)($79M)($79M)($62M)($79M)
Net Margin(87%)(102%)(127%)(96%)(102%)

Financial data powered by Morningstar, Inc.

SOPHiA Genetics Stock Performance

SOPHiA Genetics has current market cap of $351M, and enterprise value of $348M.

Market Cap Evolution


SOPHiA Genetics' stock price is $4.89.

SOPHiA Genetics share price decreased by 3.4% in the last 30 days, and increased by 57.7% in the last year.

SOPHiA Genetics has an EPS (earnings per share) of $-1.10.

See more trading valuation data for SOPHiA Genetics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$348M$351M-2.0%-3.4%-1.2%57.7%$-1.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

SOPHiA Genetics Valuation Multiples

SOPHiA Genetics trades at 4.1x EV/Revenue multiple, and (9.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for SOPHiA Genetics

EV / Revenue (LTM)


SOPHiA Genetics Financial Valuation Multiples

As of June 3, 2026, SOPHiA Genetics has market cap of $351M and EV of $348M.

SOPHiA Genetics has a P/E ratio of (4.8x).

LTMLast FY202320242025202620272028
EV/Revenue4.1x4.5x5.6x5.3x4.5x
EV/EBITDA(9.2x)(8.4x)(5.0x)(6.9x)(5.5x)
EV/EBIT(5.2x)(4.9x)(4.7x)(5.2x)(4.9x)
EV/Gross Profit6.1x6.7x8.1x7.9x6.7x
P/E(4.8x)(4.4x)(4.4x)(5.6x)(4.4x)
EV/FCF-(7.8x)(6.0x)(6.8x)(7.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified SOPHiA Genetics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

SOPHiA Genetics Margins & Growth Rates

SOPHiA Genetics grew revenue by 21% but EBITDA decreased by 21% in the last fiscal year.

In the most recent fiscal year, SOPHiA Genetics reported gross margin of 67%, EBITDA margin of (54%), and net margin of (102%).

See estimated margins and future growth rates for SOPHiA Genetics

SOPHiA Genetics Margins

Last FY202420252026202720282029
Gross Margin67%67%67%68%
EBITDA Margin(54%)(78%)(82%)(35%)
EBIT Margin(92%)(102%)(92%)(65%)
Net Margin(102%)(96%)(102%)(69%)
FCF Margin(58%)(78%)(58%)-

SOPHiA Genetics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth21%4%19%21%
Gross Profit Growth23%2%19%23%
EBITDA Growth(21%)(27%)25%(48%)
EBIT Growth(15%)(11%)7%(15%)
Net Profit Growth(18%)(21%)26%(18%)
FCF Growth-(12%)(13%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

SOPHiA Genetics Operational KPIs

SOPHiA Genetics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

SOPHiA Genetics' Rule of 40 is (14%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

SOPHiA Genetics' Rule of X is 17% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for SOPHiA Genetics
LTMLast FY202320242025202620272028
Rule of 40(24%)(14%)---
Bessemer Rule of X7%17%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue43%47%46%45%45%
G&A Expenses to Revenue62%68%85%72%66%
R&D Expenses to Revenue41%44%59%53%44%
Opex to Revenue-159%189%170%159%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

SOPHiA Genetics Competitors

SOPHiA Genetics competitors include Prenetics Global, TaiDoc Technology, ToolGen, Medical Data Vision, Cogstate, CareNet, Myriad Genetics, Abclon, Evolent Health and Atrys Health.

Most SOPHiA Genetics public comparables operate across Health Data & Analytics, Diagnostics & Genomics, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Prenetics Global3.2x2.1x(22.5x)(19.0x)
TaiDoc Technology1.8x-4.1x-
ToolGen347.6x-(13.4x)-
Medical Data Vision-9.2x--
Cogstate5.0x4.5x15.8x15.3x
CareNet----
Myriad Genetics0.6x0.6x12.7x12.8x
Abclon130.0x-(37.5x)-

This data is available for Pro users. Sign up to see all SOPHiA Genetics competitors and their valuation data.

Start Free Trial

SOPHiA Genetics VC Funding History

Before going public, SOPHiA Genetics raised $250M in total equity funding, across 6 rounds.

Last private valuation of SOPHiA Genetics was $586M, after raising $110M in October 2020 from aMoon Fund, Credit Suisse Asset Mgmt, Endeavour Vision, and 7 other investors.


SOPHiA Genetics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Oct-20Series FaMoon Fund; Credit Suisse Asset Mgmt; Endeavour Vision; Era Funding Administration; Eurazeo; Famillie C (Clarins Family); Generation Investment Management; Hitachi Ventures; Pictet Private Equity Investors S.A.; Swisscom Ventures$110M$586MSOPHiA GENETICS, a Swiss medtech company founded in 2011, operates the world’s largest data-driven medicine community network via its universal AI platform that translates complex medical data, including genomic profiles on cancer and rare diseases, into clinical insights for healthcare professionals. The platform is used by over 1,000 healthcare institutions worldwide and has analyzed 600,000 genomic profiles, processing up to 17,000 new profiles monthly, enabling continual learning and network effects for improved patient management. In October 2020, SOPHiA GENETICS closed an oversubscribed Series F funding round exceeding $110 million, led by aMoon Fund and Hitachi Ventures, with participation from Credit Suisse, Pictet group, Swisscom Ventures, Endeavour Vision, Generation Investment Management, Eurazeo Growth, Alychlo, ACE & Company, and Famille C Invest, matching the specified investors. The round brought the company's total fundraising to approximately $250 million since inception, targeting a valuation of $586 million as it planned to issue 10 million shares. Proceeds from the round were allocated to accelerate global expansion, particularly penetrating the U.S. and Asian markets, enhancing the platform's multimodal capabilities, and boosting adoption by healthcare institutions and biopharma for optimizing targeted therapies. The funding supports SOPHiA's decentralized model amid rising demand for data-driven medicine combining multiple data sources. New board addition Didier Hirsch, former CFO at Agilent, was appointed to chair the audit committee. The investment reflects strong confidence in SOPHiA's leadership in data-driven medicine, with quotes from aMoon's Tomer Berkovitz highlighting its role in addressing clinicians’ needs through complex data integration, and Hitachi's Keiji Kojima emphasizing expansion in Japan and beyond. This round positions SOPHiA to meet growing clinical and biopharma demand while competing in a market with players like Owkin.
Jan-19Series EAlychlo; Balderton Capital; Generation Investment Management; Idinvest Partners$77M-SOPHiA GENETICS, a Swiss-founded health-tech company co-based in Lausanne and Boston, develops an AI-powered SaaS platform for data-driven medicine, applying machine learning to genomic and radiomic data from DNA sequencing to enable personalized and preventive treatments, described as the democratization of sequencing expertise. The Series E funding round closed on January 4, 2019, raising $77 million led by Generation Investment Management, with participation from Idinvest Partners (now part of Eurazeo), and existing investors Balderton Capital and Alychlo, bringing total funding to $140 million since 2011. At the time, the platform connected over 850 hospitals globally, up from 350 the prior year, adding about 10 new hospitals monthly, with recent additions including radiomics for tumor evolution prediction to inform treatments. The funds were allocated to expand hospital adoption worldwide, particularly ramping up U.S. hiring and growth, amid a push into biopharma for accelerating targeted therapies. Generation Investment Management highlighted SOPHiA GENETICS' leadership in leveraging genetic sequencing and digital analysis for sustainable healthcare and improved outcomes via targeted therapeutics. This Series E preceded a $110 million oversubscribed Series F in October 2020 with many of the same investors including Generation Investment Management and Alychlo, plus newcomers like Hitachi Ventures and aMoon, focused on U.S./Asia expansion, multimodal platform enhancements, and biopharma collaboration. The company later went public via IPO in July 2021 raising $234 million.
Sep-17Series D360 Capital; Alychlo; Balderton Capital; Invoke Capital$30M-SOPHiA GENETICS, a Swiss-based company founded in 2011, develops a cloud-based AI platform that analyzes large volumes of genomic data to aid in diagnosing patient illnesses, positioning itself as a leader in data-driven medicine and genomic software akin to foundational layers in PCs or smartphones. The platform integrates machine learning, has been validated across over 340 DNA sequencers, and achieves high accuracy with 99.9-100% sensitivity and 99-100% specificity. At the time of the funding, it was used by over 300 hospitals in 53 countries, supporting thousands of clinicians and analyzing genomic profiles of over 125,000 patients, with around 8,000 patients diagnosed monthly. On September 13, 2017, SOPHiA GENETICS raised $30 million in a Series D funding round led by Balderton Capital, with participation from 360 Capital Partners and existing investors including Invoke Capital (backed by Mike Lynch) and Alychlo (Mark Coucke). This brought total funding to approximately $60 million, following prior raises totaling around $28.75-30 million since inception. The proceeds were earmarked to accelerate global deployment of its SaaS platform, expand commercial activities into Latin America, Asia-Pacific, Canada, and the U.S., hire more staff (from 150 employees), and enhance development. The company emphasized building the world's largest clinical genomics community through network effects, where clinicians contribute diagnostic knowledge to improve the AI's intelligence with each analysis. Later developments include a 2021 IPO raising $234 million at $18 per share for a $1.2 billion market cap, and a 2026 Series F of $110 million led by aMoon and Hitachi Ventures, with the platform then used by over 1,000 institutions analyzing 600,000 profiles.
Dec-15Series CMarc Coucke; Reference Capital SA$15M-SOPHiA Genetics, a Switzerland-based leader in Data Driven Medicine, closed a $15 million Series C financing round on December 16, 2015, led by Alychlo, the investment firm of Marc Coucke, with participation from existing shareholders including Reference Capital. The funds supported rapid market expansion and broadening its range of genomic tests. The company provides a cloud-based SaaS platform that enables hospitals and labs to perform accurate genomic analysis for cancer and genetic diseases, ensuring data privacy and simplifying bioinformatics. At the time, SOPHiA Genetics had demonstrated strong growth, making precision medicine accessible to 25,000 patients through superior analytical performance. It had previously raised capital, including a Series B round of $13.8 million with Swisscom Ventures. Marc Coucke, founder of Omega Pharma which generated €1.27 billion in revenue in 2014, highlighted the company's potential in scalable genomic testing for cancer diagnosis. The round positioned SOPHiA Genetics as a flagship of Swiss innovation in the Health Valley, backed by prominent European life science investors like Mike Lynch of Invoke Capital.
Jul-14Series BEndeavour Vision; Invoke Capital; Swisscom Ventures$14M-Sophia Genetics raised $13.75 million in Series B financing in July 2014 in a round led by Invoke Capital, with participation from Endeavour Vision and Swisscom Ventures. The company, founded in 2011, is a European bioinformatics specialist focused on Data-Driven Medicine, providing clinical analytics for genetic disease diagnosis through Next Generation Sequencing (NGS) analysis and predictive algorithms. The investment was intended to accelerate European adoption of the company's clinical analytics platform and provide access to Invoke Capital's portfolio company Genalys, combining Sophia's genomic expertise with advanced data science capabilities. By the time of this funding round, Sophia Genetics had developed bioinformatics pipelines and visualization tools for more than 70 commercial and proprietary custom panels, obtained CE-IVD marking for supported pipelines, and achieved ISO 13485 certification. The company's technology focused on providing clinicians and hospitals across Europe with accurate clinical analytics for early diagnosis and optimized treatment of cancer and genetic diseases, leveraging a patent-pending genomic privacy approach compliant with European Data Privacy Laws.
Dec-13Series A-$4M--

Acquisitions by SOPHiA Genetics

SOPHiA Genetics has acquired 1 company to date.

Last acquisition by SOPHiA Genetics was on June 17th 2018. SOPHiA Genetics acquired Interactive Biosoftware for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by SOPHiA Genetics

Interactive Biosoftware
Description
Interactive Biosoftware is a Rouen, France-headquartered developer of software for genetic analysis in healthcare and life sciences, particularly molecular biology. Founded in April 2007 by medical and computer scientists, the company provides tools for geneticists to perform variant annotation, surveillance, and data sharing across genome research tiers. Its Alamut Batch engine, launched in 2012, excels in high-throughput analysis with detailed RNA splicing data.
HQ CountryFrance
HQ City
Rouen
Deal Date17 Jun 2018
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all SOPHiA Genetics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About SOPHiA Genetics

When was SOPHiA Genetics founded?SOPHiA Genetics was founded in 2011.
Where is SOPHiA Genetics headquartered?SOPHiA Genetics is headquartered in France.
How many employees does SOPHiA Genetics have?As of today, SOPHiA Genetics has over 423 employees.
Who is the CEO of SOPHiA Genetics?SOPHiA Genetics' CEO is Jurgi Camblong.
Is SOPHiA Genetics publicly listed?Yes, SOPHiA Genetics is a public company listed on Nasdaq.
What is the stock symbol of SOPHiA Genetics?SOPHiA Genetics trades under SOPH ticker.
When did SOPHiA Genetics go public?SOPHiA Genetics went public in 2021.
Who are competitors of SOPHiA Genetics?SOPHiA Genetics main competitors include Prenetics Global, TaiDoc Technology, ToolGen, Medical Data Vision, Cogstate, CareNet, Myriad Genetics, Abclon, Evolent Health, Atrys Health.
What is the current market cap of SOPHiA Genetics?SOPHiA Genetics' current market cap is $351M.
What is the current revenue of SOPHiA Genetics?SOPHiA Genetics' last 12 months revenue is $84M.
What is the current revenue growth of SOPHiA Genetics?SOPHiA Genetics revenue growth (NTM/LTM) is 21%.
What is the current EV/Revenue multiple of SOPHiA Genetics?Current revenue multiple of SOPHiA Genetics is 4.1x.
Is SOPHiA Genetics profitable?No, SOPHiA Genetics is not profitable.
What is the current EBITDA of SOPHiA Genetics?SOPHiA Genetics has negative EBITDA and is not profitable.
What is SOPHiA Genetics' EBITDA margin?SOPHiA Genetics' last 12 months EBITDA margin is (45%).
What is the current EV/EBITDA multiple of SOPHiA Genetics?Current EBITDA multiple of SOPHiA Genetics is (9.2x).
How many companies SOPHiA Genetics has acquired to date?As of June 2026, SOPHiA Genetics has acquired 1 company.
What was the largest acquisition by SOPHiA Genetics?None of the M&A deals SOPHiA Genetics has completed have disclosed valuations.
What companies SOPHiA Genetics acquired?SOPHiA Genetics acquired Interactive Biosoftware.
In how many companies SOPHiA Genetics has invested to date?SOPHiA Genetics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to SOPHiA Genetics

Lists including SOPHiA Genetics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial